Duloxetine Capsule, Delayed Release
Product Images NDC 68180-296

20 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68180-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 01)

Structure (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 01)
Chemical structure of duloxetine hydrochloride, showing its distinct molecular framework including a naphthalene group attached to a thiophene ring and an amine side chain with a hydrochloride component.*
FDA Label Image

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 02)

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 02)
A Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over time for Duloxetine versus placebo. The x-axis represents days from randomization to relapse up to 200 days, and the y-axis shows the proportion of patients with relapse ranging from 0 to 1. The chart plots two lines: a solid line for Duloxetine and a dashed line for placebo, illustrating a lower relapse proportion in the Duloxetine group throughout the period.*
FDA Label Image

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 03)

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 03)
A Kaplan-Meier curve chart depicting the proportion of patients with relapse over time from randomization to relapse (days). The graph compares two treatments: Duloxetine (solid line) and placebo (dashed line), with the placebo group showing a higher proportion of relapse over time.*
FDA Label Image

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 04)

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 04)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily, and placebo over a range of pain improvement percentages from 0% to 100%.*
FDA Label Image

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 05)

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 05)
A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Three groups are compared: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph illustrates the relationship between pain improvement percentage and the proportion of patients reporting such improvement for each treatment group.*
FDA Label Image

Fig 5 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 06)

Fig 5 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 06)
A line graph showing percentage of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. The graph compares Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and placebo, with lines illustrating higher improvement percentages for both Duloxetine groups compared to placebo across increasing pain improvement thresholds.*
FDA Label Image

Fig 6 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 07)

Fig 6 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 07)
A line chart showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two separate lines), and placebo, illustrating patient response to Duloxetine at different dosages in terms of pain improvement.*
FDA Label Image

Fig 7 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 08)

Fig 7 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 08)
A line graph showing the percentage of pediatric patients aged 13 to 17 with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12 in Study FM-4. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved (0 to 100%). Two lines compare Duloxetine 60 mg once daily and placebo, with Duloxetine showing higher percentages of patients improved across most pain relief levels.*
FDA Label Image

Figure 8 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 09)

Figure 8 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 09)
A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement ranging from >0 to 100%, and the y-axis shows the percentage of patients improved, from 0 to 100%. Duloxetine is represented by a solid line with diamonds, showing higher patient improvement percentages across most improvement levels compared to placebo, which is a dashed line with x's.*
FDA Label Image

Figure 9 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 10)

Figure 9 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 10)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows percentage of patients improved. Two lines represent Duloxetine and placebo trends in patient improvement across pain reduction percentages.*
FDA Label Image

Figure 10 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 11)

Figure 10 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 11)
A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The graph shows two lines, one for Duloxetine and one for placebo, with the Duloxetine line consistently above the placebo line, indicating higher patient improvement percentages at various pain improvement thresholds.*
FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)
Duloxetine 60 mg delayed-release capsules by Lupin Pharmaceuticals, Inc. The capsule is orange and black with printed text appearing on the orange body. This oral human prescription drug is available in the strength of 60 mg in this label depiction.*
FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)
Duloxetine delayed-release capsules in varying strengths including 20 mg, 30 mg, 40 mg, and 60 mg, manufactured by Lupin Pharmaceuticals, Inc. The image shows multiple green and white capsules arranged in a pattern on a white background without visible text or additional packaging details.*
FDA Label Image

20mg-60s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 12)

20mg-60s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 12)
Label for Duloxetine Delayed-Release Capsules USP, 20 mg, from Lupin Pharmaceuticals, Inc. The label indicates a prescription drug with 60 capsules per container. The label includes directions for pharmacists to dispense the medication guide to each patient and storage instructions. It features a barcode, manufacturing information, and a QR code linking to the medication guide.*
FDA Label Image

20mg-1000s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 13)

20mg-1000s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 13)
Label for Duloxetine Delayed-Release Capsules USP 20 mg by Lupin Pharmaceuticals, Inc. The label indicates a package size of 1,000 capsules and includes storage instructions, dosage reference, and manufacturer details. It features the NDC 68180-294-03 and a QR code for prescribing information.*
FDA Label Image

30mg-30s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 14)

30mg-30s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 14)
Label for Duloxetine Delayed-Release Capsules, USP 30 mg by Lupin Pharmaceuticals, Inc. The label includes NDC 68180-295-06, directions for use, manufacturing details specifying Lupin Pharmaceuticals, Inc. in the US and Lupin Limited in India, barcode, QR code for medication guide, and storage instructions. The label indicates a package size of 30 capsules.*
FDA Label Image

30mg-1000s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 15)

30mg-1000s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 15)
Duloxetine 30 mg delayed-release capsules label from Lupin Pharmaceuticals, Inc. The label shows dosage form as capsules, delayed-release for oral use, with a package count of 1,000 capsules. The label includes storage instructions and the manufacturer information: Lupin Limited, Goa, India, and Lupin Pharmaceuticals, Naples, FL. The NDC on the label is 68180-295-03.*
FDA Label Image

40mg-30s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 16)

40mg-30s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 16)
Label for Duloxetine Delayed-Release Capsules, USP 40 mg by Lupin Pharmaceuticals, Inc. The label includes the NDC 68180-297-06, instructions to dispense the medication guide, and states the package contains 30 delayed-release capsules. Storage instructions and manufacturing details are also visible, including a QR code for the medication guide.*
FDA Label Image

60mg-30s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 17)

60mg-30s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 17)
Label for Duloxetine Delayed-Release Capsules USP 60 mg by Lupin Pharmaceuticals, Inc. The label indicates 30 capsules per container and includes storage instructions, manufacturing details, a barcode, and a QR code linking to the medication guide. The capsules are delayed-release and intended for oral use.*
FDA Label Image

60mg-1000s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 18)

60mg-1000s (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 18)
Label for Duloxetine Delayed-Release Capsules, USP 60 mg by Lupin Pharmaceuticals, Inc. The label shows NDC 68180-296-03, indicates a package of 1,000 capsules, and includes directions for pharmacists to dispense the medication guide. Storage instructions and manufacturer information for Lupin Pharmaceuticals, Naples, FL, and Lupin Limited, India, are included along with a barcode and QR code for prescribing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.